Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.
ROcuronium Bromide 50 mg/5 mL ( 10 mg/mL) Recalled by New England Life Care, Inc. dba Advanced Compounding Solutions Due to CGMP Violations- that spaces adjacent to the production...
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact New England Life Care, Inc. dba Advanced Compounding Solutions directly.
Affected Products
ROcuronium Bromide 50 mg/5 mL ( 10 mg/mL), 5mL Syringe, RX Only, Advanced Compounding Solutions, 4 Constitution Way Ste L Woburn, MA 01801-1042, NDC: 71546-090-05
Quantity: 500 Syringes
Why Was This Recalled?
CGMP Violations- that spaces adjacent to the production area may have been compromised at the time of production.
Where Was This Sold?
This product was distributed nationwide across all 50 states.
About New England Life Care, Inc. dba Advanced Compounding Solutions
New England Life Care, Inc. dba Advanced Compounding Solutions has 5 total recalls tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc · March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. · March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report